$1.59
1.27% yesterday
Nasdaq, Apr 28, 10:00 pm CET
ISIN
US14817C1071
Symbol
SAVA
Sector
Industry

Cassava Sciences, Inc. Stock price

$1.59
-0.06 3.64% 1M
-25.14 94.05% 6M
-0.77 32.63% YTD
-20.71 92.87% 1Y
-19.31 92.39% 3Y
-5.82 78.54% 5Y
-13.25 89.29% 10Y
Nasdaq, Closing price Mon, Apr 28 2025
+0.02 1.27%
ISIN
US14817C1071
Symbol
SAVA
Sector
Industry

Key metrics

Market capitalization $76.81m
Enterprise Value $-51.76m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.44
P/B ratio (TTM) P/B ratio 0.53
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-148.35m
Free Cash Flow (TTM) Free Cash Flow $-117.03m
Cash position $128.57m
EPS (TTM) EPS $-1.45
Short interest 23.21%
Show more

Is Cassava Sciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Cassava Sciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Cassava Sciences, Inc.:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast Cassava Sciences, Inc.:

Hold
100%

Financial data from Cassava Sciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 1.13 1.13
26% 26%
-
-1.13 -1.13
26% 26%
-
- Selling and Administrative Expenses 76 76
468% 468%
-
- Research and Development Expense 70 70
22% 22%
-
-147 -147
41% 41%
-
- Depreciation and Amortization 1.13 1.13
26% 26%
-
EBIT (Operating Income) EBIT -148 -148
40% 40%
-
Net Profit -24 -24
75% 75%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cassava Sciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cassava Sciences, Inc. Stock News

Neutral
GlobeNewsWire
7 days ago
AUSTIN, Texas, April 21, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments, including simufilam, for central nervous system (CNS) disorders such as tuberous sclerosis complex (TSC)-related epilepsy, today announced the retirement of James W. Kupiec, MD, Chief Me...
Negative
Reuters
about one month ago
The biotechnology company Cassava Sciences failed on Wednesday to end a malicious prosecution lawsuit by doctors and short-sellers who expressed doubts about its experimental, soon-to-be-discontinued Alzheimer's drug simufilam.
Neutral
GlobeNewsWire
about one month ago
AUSTIN, Texas, March 25, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing a novel, investigational treatment for central nervous system disorders, including Alzheimer's disease (AD) dementia and tuberous sclerosis complex (TSC)-related epilepsy, today shared topline results from the Phase 3 REF...
More Cassava Sciences, Inc. News

Company Profile

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.

Head office United States
CEO Richard Barry
Employees 30
Founded 1998
Website www.cassavasciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today